TAGMO Clinical Readouts -- Initial results for head and neck, and upper GI adenocarcinoma cohorts are expected midyear, with ...

CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN.

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 ...

Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and ...

For the past two years, the healthcare industry has been talking about artificial intelligence, but 2026 is the year it started proving it. With the FDA authorizing over 1,357 AI-enabled medical ...

Detailed price information for Zai Lab Ltd ADR (ZLAB-Q) from The Globe and Mail including charting and trades.

Amgen (AMGN) stock is in focus as partner Kissei (KSPHF) reports 20 deaths linked to the U.S. company's rare disease drug.

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight The oligonucleotides clinical trial analysis report delivers important ...

Precigen’s management framed Q1 2026 as the first full quarter of PAPZIMEOS availability, citing $21.6 million of net product revenue and describing continued momentum into Q2 supported by broad ...

Germany's Merck KGaA on Wednesday ​raised its 2026 adjusted ‌operating profit guidance range, citing stronger momentum at ...

Thursday, May 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot ...

According to MarketsandMarkets, the Pharmaceutical Drug Delivery Market is projected to grow from about USD 2,152.45 billion in 2026 to USD 2 ...